Market Overview

US Stock Futures Fall Ahead Of Federal Budget

US Stock Futures Fall Ahead Of Federal Budget
Related ADSK
10 Stocks To Watch For May 20, 2015
Autodesk Posts Upbeat Q1 Results, But Issues Weak Forecast
Autodesk Gains from Cloud-Based Services: Time to Invest? - Analyst Blog (Zacks)
Related SPEX
Stocks Hitting 52-Week Lows
Morning Market Losers

Pre-open movers

US stock futures dropped in early pre-market trade, ahead of jobs data. The US Treasury monthly budget report for December will be released at 2:00 p.m. ET. Futures for the Dow Jones Industrial Average tumbled 29 points to 16,352.00, while the Standard & Poor's 500 index futures dropped 5.20 points to 1,832.50. Futures for the Nasdaq 100 index fell 10.25 points to 3,551.25.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index surging 0.59%, London's FTSE 100 index dropping 0.03% and STOXX Europe 600 Index climbing 0.14%. German DAX 30 index rose 0.15% and French CAC 40 Index surged 0.10%. Italian industrial production climbed by 0.3% in November from October.

Asian markets ended mostly higher today. China's Shanghai Composite fell 0.19%, Hong Kong's Hang Seng Index climbed 0.19% and India's BSE Sensex rose 1.95%.

Broker Recommendation

Analysts at Morgan Stanley upgraded Autodesk (NASDAQ: ADSK) from “equal-weight” to “overweight.” The target price for Autodesk is set to $60.

Autodesk's shares closed at $51.47 on Friday.

Breaking news

  • Spherix (NASDAQ: SPEX) announced today a second settlement and license agreement under the CompuFill patents acquired in September 2013. To read the full news, click here.
  • JinkoSolar (NYSE: JKS) today announced that its Board of Directors has authorized the exploration of strategic alternatives with respect to JinkoSolar's downstream solar PV project business. To read the full news, click here.
  • AT&T (NYSE: T) today announced that the company will hire workers for 116 jobs in Kentucky, including 34 new jobs. To read the full news, click here.
  • Genzyme, a Sanofi company (NYSE: SNY), and Alnylam Pharmaceuticals (NASDAQ: ALNY) announced today that they have significantly expanded their strategic agreement to develop and commercialize treatments for rare genetic diseases. To read the full news, click here.

Posted-In: Morgan Stanley US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets


Related Articles (ADSK + ALNY)

Around the Web, We're Loving...